Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

132
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
132
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

208
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
208
Endocarditis I: Introduction01:25

Endocarditis I: Introduction

272
Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
272
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

241
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
241
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

100
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
100
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

152
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corynebacterium diphtheriae as a very rare cause of infective endocarditis.

Polish archives of internal medicine·2026
Same author

Functional Status of Patients with Long-Term Mechanical Left Ventricular Assist Device Support in Relation to Physical Activity.

Journal of clinical medicine·2026
Same author

The Impact of Maternal Obesity and Diabetes on the Development of Congenital Heart Defects (CHDs) in Offspring: A Narrative Review.

Metabolites·2026
Same author

Quantitative PCR-Based Analysis of Bacterial Profiles in Periapical Lesions and Maxillary Sinus in Odontogenic Sinusitis.

International journal of molecular sciences·2026
Same author

Endocannabinoid System-Related Inflammation and Progression of Autosomal Dominant Polycystic Kidney Disease.

International journal of molecular sciences·2026
Same author

The Impact of Bacterial Infections on Delayed Hematopoietic Recovery in Patients with Acute Leukemia After Induction and Consolidation Therapy.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Dec 13, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.9K

Infective endocarditis - can we treat it more effectively?

Aneta Guzek1, Wojciech Braksator2, Zbigniew Gąsior3

  • 1Department of Laboratory Diagnostics, Section of Microbiology, Military Institute of Medicine, Warsaw, Poland.

Kardiochirurgia I Torakochirurgia Polska = Polish Journal of Cardio-Thoracic Surgery
|July 31, 2020
PubMed
Summary

Dalbavancin offers a promising alternative for treating infective endocarditis (IE), particularly for Staphylococcus aureus infections. This antibiotic shows high efficacy and a favorable safety profile, reducing risks associated with prolonged treatments.

Keywords:
Endocarditis Teamdalbavancinechocardiographyinfective endocarditis

More Related Videos

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
07:50

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues

Published on: January 7, 2019

7.2K
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Published on: June 4, 2012

17.1K

Related Experiment Videos

Last Updated: Dec 13, 2025

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.9K
An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
07:50

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues

Published on: January 7, 2019

7.2K
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Published on: June 4, 2012

17.1K

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Pharmacology

Background:

  • Infective endocarditis (IE) remains a severe condition with high mortality and complications.
  • Current guidelines recommend prolonged antibiotic therapy (weeks to months), increasing risks of toxicity and Clostridioides difficile infections.
  • Long-term hospitalization for IE incurs significant costs.

Purpose of the Study:

  • To evaluate dalbavancin as a potential therapeutic option for IE, especially staphylococcal IE.
  • To compare dalbavancin's efficacy, safety, and pharmacokinetic profile with existing treatments like vancomycin.
  • To explore dalbavancin's utility in managing Staphylococcus aureus infections, including MRSA, particularly with high vancomycin MICs.

Main Methods:

  • Review of dalbavancin's pharmacokinetic and pharmacodynamic properties.
  • Assessment of clinical efficacy and safety data for dalbavancin in IE treatment.
  • Comparison with vancomycin, focusing on adverse effects and dosing convenience.

Main Results:

  • Dalbavancin exhibits favorable pharmacokinetics with a long duration of action (up to 14 days after a single dose).
  • It demonstrates high clinical efficacy and good treatment tolerance with a favorable safety profile, lacking the organ toxicity associated with vancomycin.
  • Dalbavancin is effective against Staphylococcus aureus MRSA infections, even those with high vancomycin minimum inhibitory concentrations.

Conclusions:

  • Dalbavancin presents a safe, effective, and convenient therapeutic option for IE, particularly for staphylococcal etiologies.
  • Its dosing schedule and safety profile may reduce treatment-related adverse effects and healthcare costs.
  • Dalbavancin warrants consideration as a valuable alternative in IE management, especially for difficult-to-treat staphylococcal infections.